

TRADEMARKS



Tab settings → → → ▼
MLO 2-13-99

100968466

copy thereof.

To the Honorable Commissioner of Patents and Trademarks: Please re

1. Name of conveying party(ies):

Boehringer Mannheim Corporation

- Individual(s)
- General Partnership
- Corporation-State **Indiana**
- Other
- Association
- Limited Partnership

Additional names(s) of conveying party(ies) Yes No

2. Name and address of receiving party(ies):

Name: **Roche Diagnostics Corporation**

Internal Address:

Street Address: **9115 Hague Road**

City: **Indianapolis** State: **IN** ZIP: **46250**

- Individual(s) citizenship
- Association
- General Partnership
- Limited Partnership
- Corporation-State **Indiana**
- Other

If assignee is not domiciled in the United States, a domestic designation is Yes N
(Designations must be a separate document from Additional name(s) & address(es) Yes N

3. Nature of conveyance:

- Assignment
- Security Agreement
- Other **(Certificate evidencing name change attached.)**
- Merger
- Change of Name

Execution Date: **December 11, 1998**

4. Application number(s) or registration numbers(s):

A. Trademark Application No.(s)

See Attachment (1 sheet)

B. Trademark Registration No.(s)

See Attachment (1 sheet)

Additional numbers Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **D. Michael Young**

Internal Address:

Roche Diagnostics Corporation

Street Address: **9115 Hague Road**

City: **Indianapolis** State: **IN** ZIP: **46250**

6. Total number of applications and registrations involved:.....

68

7. Total fee (37 CFR 3.41):.....\$ **\$2,720.00 E**

- Enclosed
- Authorized to be charged to deposit account

8. Deposit account number:

02-2958

02/17/1999 DC0ATES 00000092 022958 694086

DO NOT USE THIS SPACE

01 FC:481 40.00 CH
02 FC:482 1675.00 CH

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

D. Michael Young, Reg. No. 33,819

Name of Person Signing

D. Michael Young

Signature

2/11/99

Date

Total number of pages including cover sheet, attachments, and TRADEMARK

ATTACHMENT**Roche Diagnostics Corporation – U.S. Trademark Registrations**

Reg No	Trademark	Reg. No.	Trademark
694086	UNI-TEST	2045233	PROACT
1117144	LYTETEK	2054277	ADVANTAGE
1121324	STATTEK	2062612	ENCOMPASS
1205095	CHEMSTRIP BG	2095499	SPLIT SECOND
1205096	CHEMSTRIP	2099102	SOFT TOUCH
1217083	REAGENT SET	2122961	ACCUSTAT
1279702	UNIMETER	2126029	CHEMSTRIP VET
1323188	BIOCHEMICA	2141287	ADVANTAGE H
1350276	NUTRIDOMA	2157151	INSTANT
1408490	PARTNERS IN CONTROL	2158944	TITAN
1408491	PARTNERS IN CONTROL	2158945	PHELIX
1408983	PARTNERS IN CONTROL	2171562	INSTANTPLUS
1408984	PARTNERS IN CONTROL	2220701	INSTANT DM
1613503	CEDIA	2220929	COMFORT CURVE
1735919	QUICKTAG		
1795715	EASY TEST		
1883230	ISOSTRIP		
1886563	CONNEXTION		
1902581	ADVANTAGE		
1933434	ACCUDATA		
1936004	CARDIAC T		
1985729	TRIPURE		
1997167	ADVANTAGE		
2014263	LIBERASE		
2025041	MICRAL		

ATTACHEMENT**Roche Diagnostic Corporation – U.S. Trademark Applications**

Trademark	Serial No
CHEMSTRIP CRITERION	74/693966
CLAS	74/693967
VET	74/720961
CAMIT	75/063548
SAFE-T-STIX	75/076937
SOFT TOUCH SAFE-T-STIX	75/077047
LUMI IMAGER	75/145219
HIGH PURE	75/172703
PST	75/187090
A1C CHEK	75/195883
ACCU-CHEK A1C	75/210285
COMPLETE	75/250983
ACCUTILITY	75/295594
ACCULINK	75/311881
INTELLI-SEARCH	75/394683
LIBERASE	75/411218
SIMPLICITY	75/443886
ACCU-CHEK SIMPLICITY	75/467114
GLYCARE	75/477214
INSULINK	75/477338
SAFE-T-PRO	75/487232
VOICEMATE	75/489049
SURE/CUT	75/507794
TELOTAGGG	75/511261
EYE-D	75/517550
VISIONEER	75/517557
MAGNA PURE	75/544,009
D-TECTOR	75/593059
D-TECTOR	75/593060

198706-883

ARTICLES OF MERGER
OF
ROCHE DIAGNOSTIC SYSTEMS, INC. 1988110795
INTO
BOEHRINGER MANNHEIM CORPORATION
(effective December 31, 1998) 198706-88:

In accordance with the requirements of the Indiana Business Corporation Law, the undersigned corporations, desiring to effect a merger, set forth the following facts:

ARTICLE I - SURVIVING CORPORATION

Section 1: The name of the corporation surviving the merger is ROCHE DIAGNOSTICS CORPORATION and such name has been changed (from Boehringer Mannheim Corporation) as a result of the merger.

Section 2: The surviving corporation is a domestic corporation existing pursuant to the provisions of the Indiana Business Corporation Law, incorporated on June 25, 1987.

ARTICLE II - MERGING CORPORATION

The name, state of incorporation and date of qualification to do business in Indiana of the merging corporation is as follows:

Name:	Roche Diagnostic Systems, Inc.
State of Incorporation:	New Jersey
Date of Qualification in Indiana:	November 23, 1988

ARTICLE III - PLAN OF MERGER


The Plan of merger, containing such information as required by Section 23-1-40-1-(b) of the Indiana Business Corporation Law, is set forth on Exhibit A attached hereto and made a part hereof.

ARTICLE IV - MANNER OF ADOPTION AND VOTE

1. Action by Surviving Corporation. The outstanding capital stock of the surviving corporation consists of 1,000 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

2. Action by Merging Corporation. The outstanding capital stock of the merging corporation consists of 100 shares, all designated Common Stock and entitled to vote on the merger; all votes entitled to be cast were voted by written consent, dated December 11, 1998, in favor of the merger.

IN WITNESS WHEREOF, the undersigned being the President of Boehringer Mannheim Corporation, executes these Articles of Merger and verifies, subject to penalties of perjury, that the statements contained herein are true this 11th day of December, 1998.



Dennert O. Ware
President

**AGREEMENT AND PLAN OF MERGER
OF
ROCHE DIAGNOSTIC SYSTEMS, INC.
INTO
BOEHRINGER MANNHEIM CORPORATION**

AGREEMENT AND PLAN OF MERGER dated December 11, 1998 between Boehringer Mannheim Corporation, an Indiana corporation ("BMC"), and Roche Diagnostic Systems, Inc., a New Jersey corporation ("RDS").

WITNESSETH:

WHEREAS, BMC is a corporation duly organized and existing under the laws of the State of Indiana; and

WHEREAS, RDS is a corporation duly organized and existing under the laws of the State of New Jersey; and

WHEREAS, the Boards of Directors of both BMC and RDS deem it advisable and in the best interests of their respective corporations that RDS be merged with and into BMC; now, therefore, it is agreed that

1. At the Effective Time (as that term is hereinafter defined), and upon the terms and conditions set forth in Section 3 below, RDS shall be merged with and into BMC, with BMC as the surviving corporation in such merger (the "Surviving Corporation").

2. As to each constituent corporation, the designation and number of outstanding shares of each class and series and the voting rights thereof are as follows:

<u>Corporation</u>	<u>Designation and number of shares in each class or series outstanding</u>	<u>Shares entitled to vote</u>
RDS	Common Stock, 100 shares \$1.00 par value	100 shares
BMC	Common Stock, 1,000 shares, no par value	1,000 shares

3. The terms and conditions of the merger are as follows:

A. **Share Cancellation.** In view of the fact that a single shareholder owns all of the issued and outstanding capital stock of BMC and RDS, at the Effective Time each share of the Common Stock, par value \$1.00 per share, of RDS issued and outstanding immediately prior to

the Effective Time shall be automatically canceled and certificates for such shares shall be surrendered and canceled.

B. Articles of Incorporation and By-Laws. The Articles of Incorporation and By-Laws of BMC shall continue as the Articles of Incorporation and By-Laws of the Surviving Corporation; provided, however, that Article 1 of the Articles of Incorporation shall be amended to read: "The name of the Corporation is Roche Diagnostics Corporation."

C. Shares of Surviving Corporation. Each share of the Common Stock, no par value, of BMC issued and outstanding immediately prior to the Effective Time shall continue unchanged as one share of the stock of the Surviving Corporation, without the issuance or exchange of new shares or share certificates.

D. Assets; Liabilities. At the Effective Time, all the property, real and personal, rights, privileges, immunities, powers, purposes, franchises, patents, licenses, trademarks, registrations, causes of action, and every other asset of BMC and RDS shall be transferred to, vest in and devolve upon the Surviving Corporation, without further act or deed, and every interest of BMC and RDS shall be as effectively the property of the Surviving Corporation as they were of BMC and RDS, respectively. The Surviving Corporation shall assume and be liable for all liabilities, obligations, and penalties of BMC and RDS.

E. Directors and Officers. The directors and officers of the Surviving Corporation shall continue unchanged at and after the Effective Time.

F. Abandonment. Notwithstanding the approval and adoption of this Plan and Agreement of Merger by the sole stockholder of either or both BMC and RDS, this Agreement of Merger may be terminated at any time prior to the Effective Time by the Board of Directors of either BMC or RDS.

4. Effective Time. The merger of RDS into BMC shall be effective on December 31, 1998, and for accounting purposes shall be deemed to have occurred as of 11:59 p.m. on such date (the "Effective Time").

IN WITNESS WHEREOF, the undersigned have signed this Agreement as of the date first above written.

BOEHRINGER MANNHEIM CORPORATION

By: /s/ Dennert O. Ware
Name: Dennert O. Ware
Title: President

ROCHE DIAGNOSTIC SYSTEMS, INC.

By: /s/ Vincent P. Mihalik
Name: Vincent P. Mihalik
Title: Executive Vice President